Medical Device Instructions for Use: FDA and EU MDR Requirements

Medical device Instructions for Use requirements come from two overlapping regimes: in the United States, FDA labeling rules under 21 CFR Part 801 that treat a device without adequate directions for use as misbranded, and in the European Union, the Medical Device Regulation, whose Annex I lists in detail what every IFU must say. Both regimes cover content, readability, symbols, language, and post-market updates, and both back their rules with the power to block sales, order recalls, and impose penalties.

What the FDA Requires in the IFU

U.S. federal law defines “adequate directions for use” as instructions that let a person use the device safely for its intended purpose. Directions become inadequate — and the device misbranded — when they omit any of the following: every intended use or condition the device addresses, the dose or quantity, frequency and duration of use, timing relative to other events, route or method of use, or preparation steps such as temperature adjustment or assembly.¹

The labeling must also identify the manufacturer or distributor by name and business address. For prescription devices, it must cover indications, effects, methods of administration, frequency and duration of use, and all relevant hazards, contraindications, side effects, and precautions needed for a licensed practitioner to use the device safely.²

What the EU MDR Requires in the IFU

The MDR is more granular. Annex I, Section 23.4 lists specific content elements that every IFU must contain, including the device’s intended purpose, indications, contraindications, the target patient group, and the intended users.³ Beyond those basics, the IFU must cover:

Preparation and use — any handling before the device is ready, such as sterilization, final assembly, or calibration, and the levels of disinfection needed for patient safety.
Reusable devices — cleaning, disinfection, packaging, and the validated method of re-sterilization, plus when the device should no longer be reused, such as signs of material degradation or a maximum number of reuse cycles.
Installation and maintenance — how to verify proper installation, and the nature and frequency of preventive maintenance and any required calibration over the device’s intended lifetime.
Storage and handling — any special conditions that apply.

The two regimes overlap in many places, but the MDR spells out more of what each section must address. Manufacturers selling in both markets typically build the IFU to satisfy the more detailed MDR requirements and then confirm FDA compliance against that base.³

Prescription Devices Versus Over-the-Counter Devices

The FDA draws a sharp line between devices that need professional supervision and those sold directly to consumers. A prescription device isn’t safe for use except under a licensed practitioner’s direction. Its labeling is exempt from the general “adequate directions for use” rule, but only if it carries full prescribing information covering indications, methods of use, hazards, contraindications, and side effects.² The practitioner fills the gaps that a layperson couldn’t navigate alone.

Over-the-counter devices get no such exemption. Their instructions must let a layperson with no medical training use the device safely. The principal display panel must carry the device’s common name followed by an accurate statement of what it does, in boldface. FDA patient labeling guidance recommends writing at or below an eighth-grade reading level, assuming a user with no device or medical knowledge.⁴ Specific OTC categories carry additional mandates; menstrual tampons, for example, must include consumer information about toxic shock syndrome warning signs and the importance of using the minimum absorbency needed.¹

Readability, Format, and Design

Readability is a regulatory requirement, not a suggestion. FDA guidance on patient labeling says content should flow logically in brief, simple language, with the most important information first. Similar information should be grouped together. Headings should capture main points, paragraphs should hold a single thought, and bullet formatting helps users scan for specifics.⁴

FDA draft guidance on IFU content and format adds that instructions should be action-oriented and step-by-step, with visuals placed immediately next to the related step. Each visual should demonstrate a single concept and be large enough to understand easily. White space between blocks of text separates concepts and signals topic changes.⁵ For troubleshooting sections, FDA recommends grouping similar problems, highlighting each group heading, and putting the most life-threatening problems first.⁴

Symbols and the Symbols Glossary

Medical device labeling commonly uses standardized symbols from ISO 15223-1 to convey safety and operational information across languages. The FDA recognizes this standard and permits stand-alone symbols (with no adjacent explanatory text) if specific conditions are met.⁶

Using a stand-alone symbol triggers a symbols glossary requirement. The glossary — paper or electronic — must list each symbol, the title and designation number of the standard it comes from, the symbol’s reference number, and its meaning. The device packaging must also carry a prominent statement in English identifying where the glossary can be found.⁷ In the EU, ISO 15223-1 is harmonized to the MDR, so symbols from that standard don’t need separate description in the information supplied with the device, as long as they’re used according to the standard.

Unique Device Identifier on the Label

Every medical device label and device package sold in the U.S. must bear a unique device identifier. The UDI must appear in two forms: easily readable plain text and an automatic identification and data capture format such as a barcode. If the barcode isn’t visible on visual examination, the label must disclose its presence.⁸

The UDI contains a device identifier segment and, where applicable, a production identifier conveying the lot or batch number, serial number, manufacturing date, or expiration date. Class I devices that already carry a Universal Product Code are deemed compliant; the UPC serves as the unique identifier. Stand-alone software has its own rules: it must display the UDI in plain text either at startup or through a menu command, and must include the software version number in its production identifier.⁸

Language Requirements

In the U.S., all required label statements must appear in English. The exception covers devices distributed solely in Puerto Rico or a U.S. territory where a different language predominates.⁷

The EU MDR requires the IFU in the official language or languages of each member state where the device is placed on the market or put into service. For pan-EU distribution that can mean translating a single IFU into more than 20 languages, and each translation carries the same legal weight as the original. Translation errors are treated the same as errors in the source document.

When Electronic Instructions Are Allowed

The FDA permits electronic IFU under certain conditions but expects the same content as a paper version. There is no single FDA regulation creating a blanket eIFU framework; permissibility depends on the device type, the user population, and whether paper instructions would be impractical.

The EU has a detailed eIFU framework in Commission Implementing Regulation 2021/2226, which replaced Regulation 207/2012. Two core conditions apply: the device must be intended for exclusive use by professional users, and use by other persons must not be reasonably foreseeable. Even when eIFU is permitted, the manufacturer must be able to supply a paper copy at no additional cost within seven calendar days of a request, or at the time of delivery if requested when ordering. The device or an accompanying document must clearly tell users how to access the electronic version and how to request paper.⁹

Proving the IFU Works: Human Factors Validation

Writing clear instructions isn’t enough. The FDA expects manufacturers to prove they work. Its human factors and usability engineering guidance describes a validation process (sometimes called summative usability testing) that indirectly assesses whether the IFU supports safe and effective use. Test participants perform critical tasks with the device while using the labeling as written. Researchers record use errors and near-misses, then interview participants about difficulties, including whether they misinterpreted or failed to notice device labels.¹⁰

The labeling used in these tests must represent the final design. If testing reveals use errors on critical tasks, the manufacturer cannot simply state in a premarket submission that the risks were mitigated by modifying the IFU. Additional test data must show the modified instructions actually reduced the risk to acceptable levels.¹⁰

The FDA’s risk hierarchy matters here too. Written warnings in a user manual are considered the least effective safety measure, below inherent safety by design and below protective measures built into the device. If a design change can’t fully eliminate a use-related hazard, labeling should still address it, but labeling shouldn’t be the primary control for critical hazards.¹⁰

Keeping the IFU Current After Launch

Regulatory obligations don’t end at market release. Under the EU MDR, manufacturers must systematically gather post-market data from complaints, adverse events, clinical evidence, and reports of off-label use, and use that information to evaluate whether the IFU needs updating. European Commission guidance treats PMS information as an input back into design and development, with IFU and labeling updates following whenever new residual risks are identified.¹¹

When evidence of new or increased risks surfaces — previously unknown side effects, systematic misuse, or off-label use patterns — the manufacturer must take appropriate action, which may include changes to the device design, the labeling, or the IFU. Significant changes may also require notifying the notified body. The FDA imposes parallel expectations through its own post-market surveillance and reporting rules, and both systems require IFU updates to run through formal change control.¹¹

What Noncompliance Costs

A device with inadequate or missing IFU is legally misbranded under federal law. Introducing a misbranded device into interstate commerce is a prohibited act under 21 U.S.C. § 331.¹² Labeling can be deficient because it lacks adequate directions for use, fails to carry adequate warnings against dangerous use, or omits required safety information.¹³

Consequences are both civil and criminal. A first violation of Section 331 carries up to one year of imprisonment, a fine of up to $1,000, or both. With a prior conviction or intent to defraud, the penalties rise to up to three years of imprisonment and a fine of up to $10,000.¹⁴

The statute sets a base civil penalty of up to $15,000 per device-related violation and up to $1,000,000 for all violations in a single proceeding, both adjusted annually for inflation. The most recently published adjustment brings the per-violation cap to $35,466 and the per-proceeding cap to $2,364,503.¹⁴ Beyond fines and prosecution, the FDA can issue warning letters, require corrective action, mandate recalls, and refuse to approve new submissions from manufacturers with unresolved labeling violations. The IFU sits in the box with the device, which makes labeling one of the easier findings for an inspector to make.

1
eCFR. 21 CFR Part 801 – Labeling
2
eCFR. 21 CFR 801.109 – Prescription Devices
3
European Commission Health. Annex VI – Checklist of General Safety and Performance Requirements
4
Food and Drug Administration. Guidance on Medical Device Patient Labeling – Final Guidance for Industry and FDA Reviewers
5
FDA. Instructions for Use Content and Format Draft Guidance
6
U.S. Food and Drug Administration. Recognized Consensus Standards – Medical Devices
7
eCFR. 21 CFR 801.15 – Medical Devices; Prominence of Required Label Statements; Use of Symbols in Labeling
8
eCFR. Subpart B – Labeling Requirements for Unique Device Identification
9
EUR-Lex. Commission Implementing Regulation (EU) 2021/2226
10
FDA. Applying Human Factors and Usability Engineering to Medical Devices
11
European Commission. Guidance on Post-Market Surveillance of Medical Devices and In Vitro Diagnostic Medical Devices
12
Office of the Law Revision Counsel. 21 USC 331 – Prohibited Acts
13
Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices
14
Office of the Law Revision Counsel. 21 USC 333 – Penalties